Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURN-COVID Biobank
NL-OMON52215Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of casirivimab + imdevimab, sotrovimab, bamlanivimab + etesevimab, tixagevimab + cilgavimab, molnupiravir and 1 more in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoints: SARS-CoV-2 viral load kinetics during and after treatment, Risk of SARS-CoV-2 infection after prophylactic use and 2 more. Started Dec 2021; status: recruiting.
02
Drugs
casirivimab + imdevimabsotrovimabbamlanivimab + etesevimabtixagevimab + cilgavimabmolnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52215.